Hikma Pharmaceuticals Plc Hikma announces agreement with Sciecure Pharma
January 03 2019 - 4:00AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
03 January 2019
London, 3 January 2019 - Hikma Pharmaceuticals PLC (Hikma,
Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1
Moody's / BB+ S&P, both stable) announces an exclusive license,
supply and distribution agreement between its wholly-owned
subsidiary Hikma Pharmaceuticals International Limited and Beijing
Sciecure Pharmaceutical Co., Ltd (Sciecure), a leading Chinese
company that researches, develops and manufactures high-quality
pharmaceutical products for global markets.
The agreement provides Hikma with exclusive rights to sell one
of Sciecure's niche injectable anti-viral medicines across the US
for a minimum of eight years, with an option to extend this
partnership for an additional two years. Sciecure expects to file
this product for approval with the US Food and Drug Administration
in early 2019.
"We are thrilled to partner with Sciecure, an innovative and
vertically integrated company capable of producing high-quality
products across the pharmaceutical spectrum from API to finished
doses," said Daniel Motto, Hikma's Executive Vice President of
Commercial and Business Development. "Our partnership with Sciecure
is another example of how Hikma is continuing to expand its
pipeline, targeting both niche products and high-volume
opportunities, in order to offer a broad portfolio of high-quality
medicines to US patients, physicians and hospitals."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal +44 (0)20 7399 2760/ +44 7776
EVP, Strategic Planning and Global 477050
Affairs uk-investors@hikma.com
Steven Weiss +1 732 720 2830/ +1 732 788 8279
Senior Director, Communications sweiss@hikma.com
and Public Affairs
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. Head-quartered in the
UK, we're a global company with a local presence across the United
States (US), the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 8,500 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner in the MENA region, and through our
venture capital arm, are helping bring innovative health
technologies to people around the world. For more information,
please visit www.hikma.com.
About Sciecure
Beijing Sciecure Pharmaceutical Co., Ltd (Sciecure), is a
leading China-based multi-national specialty pharmaceutical company
which focuses on researching, developing and manufacturing
high-barrier and complex medicines. Sciecure's fully-integrated
capabilities include research and development, API production,
manufacturing and commercialization, in addition to strong clinical
and regulatory experience. The company operates in Asia, Europe and
North America, and maintains US-based business offices and a
research and development laboratory in Monmouth Junction, NJ
(Sciecure Laboratories, LLC).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABRGDBGDGBGCD
(END) Dow Jones Newswires
January 03, 2019 04:00 ET (09:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024